Cargando…

Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies

BACKGROUND: This meta-analysis was conducted to determine the efficacy, safety and tolerability of tofacitinib in the treatment of rheumatoid arthritis in patients with an inadequate response or intolerance to at least one of the nonbiologic or biologic disease-modifying antirheumatic drugs (DMARDs)...

Descripción completa

Detalles Bibliográficos
Autor principal:	Berhan, Asres
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222887/ https://www.ncbi.nlm.nih.gov/pubmed/24279308 http://dx.doi.org/10.1186/1471-2474-14-332

Ejemplares similares

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
por: Berhan, Asres, et al.
Publicado: (2013)

Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
por: Abdulkader, Omer Ahmad Fatheddin, et al.
Publicado: (2016)

Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
Publicado: (2017)

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
por: Song, Gwan Gyu, et al.
Publicado: (2014)

Is Desvenlafaxine Effective and Safe in the Treatment of Menopausal Vasomotor Symptoms? A Meta-analysis and Meta-regression of Randomized Double-blind Controlled Studies
por: Berhan, Yifru, et al.
Publicado: (2014)

Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials
por: Berhan, Asres, et al.
Publicado: (2014)

A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
por: Panchal, Viraj, et al.
Publicado: (2023)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety
por: Bird, Paul, et al.
Publicado: (2019)

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
por: Berhan, Asres, et al.
Publicado: (2013)

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials
por: Wu, Zhi-Peng, et al.
Publicado: (2018)

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
por: Ha, So-Young, et al.
Publicado: (2021)

Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?
por: Ganapati, Arvind, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
por: Leng, Xiaomei, et al.
Publicado: (2023)

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study
por: Agarwal, Piyush, et al.
Publicado: (2018)

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
por: Hasni, Sarfaraz A., et al.
Publicado: (2021)

A Meta-Analysis of Drug Resistant Tuberculosis in Sub-Saharan Africa: How Strongly Associated with Previous Treatment and HIV Co-Infection?
por: Berhan, Asres, et al.
Publicado: (2013)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Is the Sexual Behaviour of HIV Patients on Antiretroviral therapy safe or risky in Sub-Saharan Africa? Meta-Analysis and Meta-Regression
por: Berhan, Asres, et al.
Publicado: (2012)

Meta-analyses of fertility desires of people living with HIV
por: Berhan, Yifru, et al.
Publicado: (2013)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

A Meta-Analysis of Selected Maternal and Fetal Factors for Perinatal Mortality
por: Berhan, Yifru, et al.
Publicado: (2014)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

A Meta-Analysis of Socio-Demographic Factors Predicting Birth in Health Facility
por: Berhan, Yifru, et al.
Publicado: (2014)

A Meta-Analysis of Risky Sexual Behaviour among Male Youth in Developing Countries
por: Berhan, Yifru, et al.
Publicado: (2015)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

A Meta-Analysis of Socio-Demographic Factors for Perinatal Mortality in Developing Countries: A Subgroup Analysis of the National Surveys and Small Scale Studies
por: Berhan, Yifru, et al.
Publicado: (2014)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
por: Moradi, Soroush, et al.
Publicado: (2020)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: He, Ying, et al.
Publicado: (2013)

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019)

Safety and Tolerance of a Novel Anti-Regurgitation Formula: A Double-Blind, Randomized, Controlled Trial
por: Bellaiche, Marc, et al.
Publicado: (2021)

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q53imn4ifpsnsod8mlmm64bjeq